NI201600051A - Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores - Google Patents
Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladoresInfo
- Publication number
- NI201600051A NI201600051A NI201600051A NI201600051A NI201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A
- Authority
- NI
- Nicaragua
- Prior art keywords
- combinations
- desacetilase
- histone
- inhibitors
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889640P | 2013-10-11 | 2013-10-11 | |
| US201361911089P | 2013-12-03 | 2013-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201600051A true NI201600051A (es) | 2017-07-11 |
Family
ID=52810182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201600051A NI201600051A (es) | 2013-10-11 | 2016-04-11 | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20150105358A1 (enExample) |
| EP (1) | EP3054939A4 (enExample) |
| JP (4) | JP2016532667A (enExample) |
| KR (1) | KR20160060143A (enExample) |
| CN (1) | CN105722507A (enExample) |
| AU (1) | AU2014332147A1 (enExample) |
| CA (1) | CA2926808A1 (enExample) |
| CL (1) | CL2016000838A1 (enExample) |
| CR (1) | CR20160200A (enExample) |
| EA (1) | EA201690753A1 (enExample) |
| IL (1) | IL244923A0 (enExample) |
| MX (1) | MX2016004604A (enExample) |
| NI (1) | NI201600051A (enExample) |
| PE (1) | PE20161342A1 (enExample) |
| PH (1) | PH12016500649A1 (enExample) |
| SG (1) | SG11201602791RA (enExample) |
| WO (1) | WO2015054175A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2526093T3 (pl) | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| HK1207403A1 (en) | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| WO2015054099A1 (en) * | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| EP3055299B1 (en) * | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| PE20161342A1 (es) * | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| EP3060217B1 (en) | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| CA2970500C (en) | 2014-12-12 | 2023-08-29 | Acetylon Pharmaceuticals, Inc. | Piperidine derivatives as hdac1/2 inhibitors |
| AR104935A1 (es) | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
| TWI706937B (zh) | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| EP3468559B1 (en) | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| JP7100018B2 (ja) | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| EP3544600A4 (en) * | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF |
| EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| PL2526093T3 (pl) * | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| NZ610225A (en) * | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| PE20161342A1 (es) * | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
-
2014
- 2014-10-07 PE PE2016000490A patent/PE20161342A1/es not_active Application Discontinuation
- 2014-10-07 SG SG11201602791RA patent/SG11201602791RA/en unknown
- 2014-10-07 JP JP2016521758A patent/JP2016532667A/ja active Pending
- 2014-10-07 CR CR20160200A patent/CR20160200A/es unknown
- 2014-10-07 KR KR1020167011860A patent/KR20160060143A/ko not_active Withdrawn
- 2014-10-07 WO PCT/US2014/059387 patent/WO2015054175A1/en not_active Ceased
- 2014-10-07 US US14/508,072 patent/US20150105358A1/en not_active Abandoned
- 2014-10-07 EA EA201690753A patent/EA201690753A1/ru unknown
- 2014-10-07 CN CN201480062094.3A patent/CN105722507A/zh active Pending
- 2014-10-07 EP EP14851888.9A patent/EP3054939A4/en not_active Withdrawn
- 2014-10-07 MX MX2016004604A patent/MX2016004604A/es unknown
- 2014-10-07 AU AU2014332147A patent/AU2014332147A1/en not_active Abandoned
- 2014-10-07 CA CA2926808A patent/CA2926808A1/en not_active Abandoned
-
2016
- 2016-04-05 IL IL244923A patent/IL244923A0/en unknown
- 2016-04-08 PH PH12016500649A patent/PH12016500649A1/en unknown
- 2016-04-11 NI NI201600051A patent/NI201600051A/es unknown
- 2016-04-11 CL CL2016000838A patent/CL2016000838A1/es unknown
-
2018
- 2018-11-30 JP JP2018225287A patent/JP7403950B2/ja active Active
-
2019
- 2019-11-15 US US16/684,809 patent/US20200323849A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020680A patent/JP2021073314A/ja active Pending
-
2023
- 2023-10-26 JP JP2023184173A patent/JP2024010118A/ja active Pending
-
2025
- 2025-03-05 US US19/071,232 patent/US20260021093A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016000838A1 (es) | 2016-11-25 |
| US20150105358A1 (en) | 2015-04-16 |
| CR20160200A (es) | 2016-08-29 |
| MX2016004604A (es) | 2016-08-01 |
| JP2016532667A (ja) | 2016-10-20 |
| IL244923A0 (en) | 2016-05-31 |
| CN105722507A (zh) | 2016-06-29 |
| JP2024010118A (ja) | 2024-01-23 |
| AU2014332147A1 (en) | 2016-05-05 |
| WO2015054175A1 (en) | 2015-04-16 |
| CA2926808A1 (en) | 2015-04-16 |
| US20260021093A1 (en) | 2026-01-22 |
| JP2021073314A (ja) | 2021-05-13 |
| PH12016500649A1 (en) | 2016-05-30 |
| JP2019052171A (ja) | 2019-04-04 |
| EP3054939A1 (en) | 2016-08-17 |
| SG11201602791RA (en) | 2016-05-30 |
| PE20161342A1 (es) | 2016-12-31 |
| EP3054939A4 (en) | 2017-12-13 |
| KR20160060143A (ko) | 2016-05-27 |
| JP7403950B2 (ja) | 2023-12-25 |
| EA201690753A1 (ru) | 2016-07-29 |
| US20200323849A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20160200A (es) | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX393610B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres | |
| MX2018005829A (es) | Composiciones para tratar el cabello. | |
| MX383484B (es) | Método para tratar el cáncer. | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |